Bertil Lindkvist has increased his holdings in Diamyd Medical. Bertil
Lindkvist’s holdings in Diamyd Medical amount to 2,979,286 B-shares as of
September 24, 2013, which corresponds to 15.1 percent of the capital and 10.5
percent of the votes.
For further information, please contact:
Peter Zerhouni, President and CEO Diamyd Medical AB
Phone: +46 8 661 00 26. E-mail: firstname.lastname@example.org
About Diamyd Medical
Diamyd Medical is a Swedish diabetes company. The Company’s primary development
project consists of the GAD-based diabetes vaccine Diamyd®for the treatment and
prevention of autoimmune diabetes. Two Swedish researcher-initiated Phase II
studies with Diamyd®are ongoing. One study evaluates whether the diabetes
vaccine can prevent type 1 diabetes in children who are at high risk of
developing the disease, while the other study evaluates whether Diamyd®in
combination with relatively high doses of vitamin D and ibuprofen can preserve
the body's own ability to regulate the blood sugar level in children and
adolescents newly diagnosed with type 1 diabetes.
In May 2013 the Company concluded an exclusive licensing agreement with the
University of California in Los Angeles (UCLA) relating to a patent portfolio
for the therapeutic use of GABA (gamma-aminobutyric acid) and GABA receptor
agonists for the treatment and prevention of type 1 and type 2 diabetes and
other inflammation-related conditions, such as metabolic syndrome, rheumatoid
arthritis and allergies.
Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (US).
Diamyd Medical’s Series B share is traded on NASDAQ OMX First North under the
ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser. Further
information is available on the Company’s website: www.diamyd.com.
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: email@example.com. Reg. no.: 556242-3797.
GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.